173 related articles for article (PubMed ID: 8769198)
1. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
Pescovitz MD
Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
[No Abstract] [Full Text] [Related]
2. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
Transplant Proc; 1996 Aug; 28(4):2183-6. PubMed ID: 8769194
[No Abstract] [Full Text] [Related]
3. A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group.
Massari PU; Grosso S; de Boccardo G; Vásquez MC; Schiavelli RO; Sabbatiello RR; Casadei DH; Rial MC; Jost LJ; Túrin MD; Agost Carreño C A; Maggiora EC; Gadea MM
Transplant Proc; 1996 Dec; 28(6):3365-7. PubMed ID: 8962310
[No Abstract] [Full Text] [Related]
4. Interim analysis of study OLN-356: Neoral versus Sandimmune in US primary liver transplant recipients. OLN-356 Principal Investigators.
Pinson CW; Beauregard-Zollinger L
Transplant Proc; 1996 Aug; 28(4):2234-6. PubMed ID: 8769209
[No Abstract] [Full Text] [Related]
5. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
Offermann G; Korn A
Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
[No Abstract] [Full Text] [Related]
6. An open randomized parallel group study to compare Sandimmune Neoral with Sandimmune soft gelatin capsule in stable renal transplant patients.
Park K; Koh YB; Kwak JY; Kim SJ; Yoon YS; Kang CM; Kim YS
Transplant Proc; 1996 Jun; 28(3):1202-3. PubMed ID: 8658627
[No Abstract] [Full Text] [Related]
7. Safety and tolerability of Neoral in transplant recipients.
Feutren G; Wong R; Jin J; Niese D; Mellein B
Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193
[No Abstract] [Full Text] [Related]
8. Case studies: conversion from Sandimmune to Neoral in stable renal allograft recipients.
Roth D; Miller J
Transplant Proc; 1996 Aug; 28(4):2219-20; discussion 2218. PubMed ID: 8769204
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
[No Abstract] [Full Text] [Related]
10. Conversion from Sandimmune to Neoral in stable liver graft recipients.
Pollard SG; Lodge JP
Transplant Proc; 1996 Aug; 28(4):2244-6. PubMed ID: 8769213
[No Abstract] [Full Text] [Related]
11. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
12. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
Hoyer PF; Boekenkamp A; Vester U; Offner G; Brodehl J
Transplant Proc; 1996 Aug; 28(4):2259-61. PubMed ID: 8769218
[No Abstract] [Full Text] [Related]
13. A randomized, controlled trial to assess the safety of switching stable renal transplant patients from Sandimmun to Sandimmun Neoral.
Loo CS; Morad Z; Lim TO; Fan KS; Suleiman AB
Transplant Proc; 1996 Jun; 28(3):1328-9. PubMed ID: 8658680
[No Abstract] [Full Text] [Related]
14. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
[No Abstract] [Full Text] [Related]
15. Neoral conversion study: shift from Sandimmune classic formulation to Neoral in heart and lung transplant patients.
Svendsen UG; Larsen KR; Allermand H; Thayssen P; Jensen SB; Pettersson G
Transplant Proc; 1996 Aug; 28(4):2281. PubMed ID: 8769225
[No Abstract] [Full Text] [Related]
16. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
[No Abstract] [Full Text] [Related]
17. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
Gracida C; Melchor JL
Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
[No Abstract] [Full Text] [Related]
18. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group.
Brennan DC; Barbeito R; Burke J; Brayman K; Greenstein S; Chang T
Kidney Int; 1999 Aug; 56(2):685-91. PubMed ID: 10432409
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of conversion from existing to microemulsion formulation of cyclosporine.
Neumayer HH; Färber L; Budde K; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
Transplant Proc; 1996 Aug; 28(4):2207-13. PubMed ID: 8769202
[No Abstract] [Full Text] [Related]
20. Conversion from Sandimmune to Neoral in stable heart transplant recipients.
Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T
Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228
[No Abstract] [Full Text] [Related]
[Next] [New Search]
